Synopsis
Synopsis
0
VMF
0
Canada
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 679 Br, Ba
2. 7-((hydroxybis(2-thienyl)acetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane Bromide
3. Ba 679 Br
4. Ba-679 Br
5. Ba679 Br
6. Br, Ba 679
7. Bromide, Tiotropium
8. Spiriva
9. Tiotropium
1. 136310-93-5
2. Spiriva
3. Ba 679 Br
4. Tiotropium (bromide)
5. Spiriva Handihaler
6. Ba 679br
7. Ba-679 Br
8. Spiriva Respimat
9. (1r,2r,4s,5s,7s)-7-(2-hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium Bromide
10. Xx112xzp0j
11. Chembl4638964
12. 7-((hydroxybis(2-thienyl)acetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane Bromide
13. Ba-679-br
14. (1r,2r,4s,5s,7r)-7-{[2-hydroxy-2,2-bis(thiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-9-ium Bromide
15. (1r,2r,4s,5s,7s)-7-(2-hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0
16. Tiopropium
17. Tiotropium Bromide Anhydrous
18. Ba-679br
19. (1a,2b,4b,5a,7b)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane Bromide
20. Ncgc00167971-01
21. Tiotropium Bromide [inn]
22. Unii-xx112xzp0j
23. Tiotropium Bromide [usan:inn:ban]
24. Tiotropium Bromide- Bio-x
25. Schembl8625
26. Dsstox_cid_24214
27. Dsstox_rid_80122
28. Dsstox_gsid_44214
29. Schembl440873
30. Schembl7607795
31. Tiotropium Bromide [mi]
32. Chembl3189058
33. Chembl4440620
34. Dtxsid2044214
35. Chebi:90959
36. Tiotropium Bromide [usan]
37. Hms2090h20
38. Act04740
39. Act04741
40. Amy23428
41. Bcp02925
42. Tiotropium Bromide [who-dd]
43. Tox21_112598
44. Bdbm50538220
45. Mfcd00867027
46. Akos015920264
47. Akos025400979
48. Ac-1300
49. Cs-0903
50. Ks-1402
51. Tiotropium Bromide [orange Book]
52. Tiotropium Bromide(spiriva, Ba 679br)
53. As-75172
54. Bt164474
55. Hy-17360
56. Bcp0726000293
57. Cas-136310-93-5
58. T3032
59. A846824
60. Q27162952
61. (1?,2?,4?,5?,7?)-7-[(2-hydroxy-2,2-di-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane Bromide
62. (1alpha,2beta,4beta,5alpha,7beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0(2,4)]nonane Bromide
63. (1r,2r,4s,5s)-7-{[2-hydroxy-2,2-bis(thiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0(2),?]nonan-9-ium Bromide
64. (1r,2r,4s,5s,7r)-7-{[2-hydroxy-2,2-bis(thiophen-2-yl)acetyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0?,?]nonan-9-ium Bromide
65. (1r,2r,4s,5s,7s)-7-[2-hydroxy-2,2-di(2-thienyl)acetoxy]-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium Bromide
66. [(1r,2r,4s,5s)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide
67. [(1r,2r,4s,5s)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl]2-hydroxy-2,2-dithiophen-2-yl-acetate Bromide
68. 1.alpha., 2.beta., 4.beta, 5.alpha, 7.beta-7-((hydroxydi-2-thienylacetyl)oxy)-9,9-dimethyl-3-oxa-9-azoniatricyclo(3.3.1.0 Sup(2,4))nonane Bromide
69. 3-oxa-9-azoniatricyclo(3,3.1.0(2,4))nonane, 7-((hydroxydi-2-thienylacetyl)oxy)-9,9-dimethyl-, Bromide, (1alpha,2beta,4beta,5alpha,7beta)-
70. 3-oxa-9-azoniatricyclo(3.3.1.02,4)nonane, 7-((hydroxydi-2-thienacetyl)oxy)-9,9-dimethyl-, Bromide, (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-
71. 3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane, 7-[(2-hydroxy-2,2-di-2-thienylacetyl)oxy]-9,9-dimethyl-, Bromide (1:1), (1alpha,2beta,4beta,5alpha,7beta)-
72. 6.beta.,7.beta.-epoxy-3.beta.-hydroxy-8-methyl-1.alpha.h,5.alpha.h-tropanium Bromide, Di-2-thienylglycolate
73. Rel-(1r,2r,4s,5s,7s)-7-(2-hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium Bromide
74. Rel-(1r,2r,4s,5s,7s)-7-(2-hydroxy-2,2-di(thiophen-2-yl)acetoxy)-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-iumbromide
1. Tiotropiumbromide
2. Gsp 304
3. Tiotropium Cation
4. Respimat
Molecular Weight | 472.4 g/mol |
---|---|
Molecular Formula | C19H22BrNO4S2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 5 |
Exact Mass | 471.01736 g/mol |
Monoisotopic Mass | 471.01736 g/mol |
Topological Polar Surface Area | 116 Ų |
Heavy Atom Count | 27 |
Formal Charge | 0 |
Complexity | 564 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Spiriva |
PubMed Health | tiotropium |
Drug Classes | Bronchodilator |
Drug Label | SPIRIVA HandiHaler consists of a capsule dosage form containing a dry powder formulation of tiotropium intended for oral inhalation only with the HandiHaler device.Each light green, hard gelatin SPIRIVA capsule contains 18 mcg tiotropium (equivalent... |
Active Ingredient | Tiotropium bromide |
Dosage Form | Powder |
Route | Inhalation |
Strength | eq 0.018mg base/inh |
Market Status | Prescription |
Company | Boehringer Ingelheim |
Patent | 8022082; 6908928; RE38912; 7694676; RE39820; 7309707; 7642268; 7070800; 6777423 |
2 of 4 | |
---|---|
Drug Name | Spiriva respimat |
PubMed Health | tiotropium |
Drug Label | The active component of SPIRIVA RESPIMAT is tiotropium. The drug substance, tiotropium bromide monohydrate, is an anticholinergic with specificity for muscarinic receptors. It is chemically described as (1, 2, 4, 5, 7)-7-[(Hydroxydi-2-thien... |
Active Ingredient | Tiotropium bromide |
Dosage Form | Spray, metered |
Route | Inhalation |
Strength | eq 0.0025mg base/inh |
Market Status | Prescription |
Company | Boehringer Ingelheim |
Patent | 7284474; 7802568; 6977042; 5964416; 7988001; 6176242; 6453795; RE39820; 7246615; 6988496; 7896264; 7837235; 6726124; 6846413; 6149054; 7396341; 7104470 |
3 of 4 | |
---|---|
Drug Name | Spiriva |
PubMed Health | tiotropium |
Drug Classes | Bronchodilator |
Drug Label | SPIRIVA HandiHaler consists of a capsule dosage form containing a dry powder formulation of tiotropium intended for oral inhalation only with the HandiHaler device.Each light green, hard gelatin SPIRIVA capsule contains 18 mcg tiotropium (equivalent... |
Active Ingredient | Tiotropium bromide |
Dosage Form | Powder |
Route | Inhalation |
Strength | eq 0.018mg base/inh |
Market Status | Prescription |
Company | Boehringer Ingelheim |
Patent | 8022082; 6908928; RE38912; 7694676; RE39820; 7309707; 7642268; 7070800; 6777423 |
4 of 4 | |
---|---|
Drug Name | Spiriva respimat |
PubMed Health | tiotropium |
Drug Label | The active component of SPIRIVA RESPIMAT is tiotropium. The drug substance, tiotropium bromide monohydrate, is an anticholinergic with specificity for muscarinic receptors. It is chemically described as (1, 2, 4, 5, 7)-7-[(Hydroxydi-2-thien... |
Active Ingredient | Tiotropium bromide |
Dosage Form | Spray, metered |
Route | Inhalation |
Strength | eq 0.0025mg base/inh |
Market Status | Prescription |
Company | Boehringer Ingelheim |
Patent | 7284474; 7802568; 6977042; 5964416; 7988001; 6176242; 6453795; RE39820; 7246615; 6988496; 7896264; 7837235; 6726124; 6846413; 6149054; 7396341; 7104470 |
Cholinergic Antagonists
Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists. (See all compounds classified as Cholinergic Antagonists.)
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)
Bronchodilator Agents
Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)
R03BB04
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
R - Respiratory system
R03 - Drugs for obstructive airway diseases
R03B - Other drugs for obstructive airway diseases, inhalants
R03BB - Anticholinergics
R03BB04 - Tiotropium bromide
GDUFA
DMF Review : Complete
Rev. Date : 2021-04-30
Pay. Date : 2020-01-13
DMF Number : 34410
Submission : 2020-03-17
Status : Active
Type : II
Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.
GDUFA
DMF Review : Complete
Rev. Date : 2021-01-11
Pay. Date : 2020-11-04
DMF Number : 34808
Submission : 2020-04-15
Status : Active
Type : II
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
GDUFA
DMF Review : Complete
Rev. Date : 2015-01-16
Pay. Date : 2013-12-31
DMF Number : 28161
Submission : 2013-12-26
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Complete
Rev. Date : 2014-03-15
Pay. Date : 2013-09-17
DMF Number : 27524
Submission : 2013-10-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21939
Submission : 2008-09-05
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18135
Submission : 2005-03-03
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36281
Submission : 2021-10-01
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-09-03
Pay. Date : 2015-02-05
DMF Number : 28820
Submission : 2015-01-27
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-12-07
Pay. Date : 2023-07-27
DMF Number : 27120
Submission : 2013-04-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-04-20
Pay. Date : 2015-11-19
DMF Number : 29726
Submission : 2016-01-20
Status : Active
Type : II
Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.
TIOTROPIUM BROMIDE MONOHYDRATE
NDC Package Code : 66412-0761
Start Marketing Date : 2020-04-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 12714-915
Start Marketing Date : 2015-05-21
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (5kg/5kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54239-011
Start Marketing Date : 2014-10-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
TIOTROPIUM BROMIDE MONOHYDRATE
NDC Package Code : 63190-0560
Start Marketing Date : 2004-01-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
TIOTROPIUM BROMIDE MONOHYDRATE
NDC Package Code : 63190-0380
Start Marketing Date : 2011-07-04
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
TIOTROPIUM BROMIDE MONOMETHANOLATE
NDC Package Code : 63190-0640
Start Marketing Date : 2004-01-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
TIOTROPIUM BROMIDE MONOHYDRATE
NDC Package Code : 61662-0021
Start Marketing Date : 2023-07-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2027-03-31
US Patent Number : 9027967
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 21936
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-03-31
Patent Expiration Date : 2028-09-13
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE
US Patent Number : 7837235*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 206756
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-09-13
Patent Expiration Date : 2025-02-26
US Patent Number : 7284474*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 21936
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-02-26
Patent Expiration Date : 2030-04-19
US Patent Number : 9010323
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 21395
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-04-19
Patent Expiration Date : 2026-01-19
US Patent Number : 8022082
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 21395
Patent Use Code : U-1186
Delist Requested :
Patent Use Description : ADMINISTRATION OF AN I...
Patent Expiration Date : 2026-01-19
Patent Expiration Date : 2025-02-26
US Patent Number : 7284474*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 21936
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-02-26
Patent Expiration Date : 2027-03-31
US Patent Number : 9027967
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 21936
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-03-31
Patent Expiration Date : 2027-09-30
US Patent Number : 9027967*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 21936
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-09-30
Patent Expiration Date : 2025-05-12
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE
US Patent Number : 8034809
Drug Substance Claim :
Drug Product Claim :
Application Number : 206756
Patent Use Code : U-1702
Delist Requested :
Patent Use Description : TREATMENT OF COPD
Patent Expiration Date : 2025-05-12
Patent Expiration Date : 2025-11-26
US Patent Number : 7896264*PED
Drug Substance Claim :
Drug Product Claim :
Application Number : 21936
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-11-26
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
56
PharmaCompass offers a list of Tiotropium Bromide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tiotropium Bromide manufacturer or Tiotropium Bromide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tiotropium Bromide manufacturer or Tiotropium Bromide supplier.
PharmaCompass also assists you with knowing the Tiotropium Bromide API Price utilized in the formulation of products. Tiotropium Bromide API Price is not always fixed or binding as the Tiotropium Bromide Price is obtained through a variety of data sources. The Tiotropium Bromide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A SPIRIVA manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of SPIRIVA, including repackagers and relabelers. The FDA regulates SPIRIVA manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. SPIRIVA API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of SPIRIVA manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A SPIRIVA supplier is an individual or a company that provides SPIRIVA active pharmaceutical ingredient (API) or SPIRIVA finished formulations upon request. The SPIRIVA suppliers may include SPIRIVA API manufacturers, exporters, distributors and traders.
click here to find a list of SPIRIVA suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A SPIRIVA DMF (Drug Master File) is a document detailing the whole manufacturing process of SPIRIVA active pharmaceutical ingredient (API) in detail. Different forms of SPIRIVA DMFs exist exist since differing nations have different regulations, such as SPIRIVA USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A SPIRIVA DMF submitted to regulatory agencies in the US is known as a USDMF. SPIRIVA USDMF includes data on SPIRIVA's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The SPIRIVA USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of SPIRIVA suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The SPIRIVA Drug Master File in Japan (SPIRIVA JDMF) empowers SPIRIVA API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the SPIRIVA JDMF during the approval evaluation for pharmaceutical products. At the time of SPIRIVA JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of SPIRIVA suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a SPIRIVA Drug Master File in Korea (SPIRIVA KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of SPIRIVA. The MFDS reviews the SPIRIVA KDMF as part of the drug registration process and uses the information provided in the SPIRIVA KDMF to evaluate the safety and efficacy of the drug.
After submitting a SPIRIVA KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their SPIRIVA API can apply through the Korea Drug Master File (KDMF).
click here to find a list of SPIRIVA suppliers with KDMF on PharmaCompass.
A SPIRIVA CEP of the European Pharmacopoeia monograph is often referred to as a SPIRIVA Certificate of Suitability (COS). The purpose of a SPIRIVA CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of SPIRIVA EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of SPIRIVA to their clients by showing that a SPIRIVA CEP has been issued for it. The manufacturer submits a SPIRIVA CEP (COS) as part of the market authorization procedure, and it takes on the role of a SPIRIVA CEP holder for the record. Additionally, the data presented in the SPIRIVA CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the SPIRIVA DMF.
A SPIRIVA CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. SPIRIVA CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of SPIRIVA suppliers with CEP (COS) on PharmaCompass.
A SPIRIVA written confirmation (SPIRIVA WC) is an official document issued by a regulatory agency to a SPIRIVA manufacturer, verifying that the manufacturing facility of a SPIRIVA active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting SPIRIVA APIs or SPIRIVA finished pharmaceutical products to another nation, regulatory agencies frequently require a SPIRIVA WC (written confirmation) as part of the regulatory process.
click here to find a list of SPIRIVA suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing SPIRIVA as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for SPIRIVA API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture SPIRIVA as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain SPIRIVA and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a SPIRIVA NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of SPIRIVA suppliers with NDC on PharmaCompass.
SPIRIVA Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of SPIRIVA GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right SPIRIVA GMP manufacturer or SPIRIVA GMP API supplier for your needs.
A SPIRIVA CoA (Certificate of Analysis) is a formal document that attests to SPIRIVA's compliance with SPIRIVA specifications and serves as a tool for batch-level quality control.
SPIRIVA CoA mostly includes findings from lab analyses of a specific batch. For each SPIRIVA CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
SPIRIVA may be tested according to a variety of international standards, such as European Pharmacopoeia (SPIRIVA EP), SPIRIVA JP (Japanese Pharmacopeia) and the US Pharmacopoeia (SPIRIVA USP).